Study of newly diagnosed bone cancer treatment and biology
Treatments studied
Part of Cancer clinical trials.
This research study follows young people newly diagnosed with osteosarcoma (a type of bone cancer) who are receiving standard chemotherapy. Researchers will collect information about how the cancer responds to treatment and study biological samples to better understand the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 22 or younger at enrollment
- Diagnosed with high-grade osteosarcoma (either localized or spread to other areas)
- Receiving or planning to receive MAP chemotherapy with high-dose methotrexate at standard dosing
- Body size at least 0.8 m² (roughly equivalent to a small adult or larger child)
- Healthy liver, kidney, and bone marrow function to tolerate chemotherapy
- Healthy heart function (ejection fraction 50% or higher)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called OMO-103, which targets a protein called Myc that helps cancer cells grow. It is for people with advanced osteosarcoma (bone cancer) that has worsened after standard chemotherapy. The drug is given intravenously (through a vein), and the study will check if it is safe and shrinks tumors.
This is an observational study (it mainly watches and records care) for people with high-grade osteosarcoma in an arm or leg. It may help doctors learn which care approaches work best for younger patients with localized disease.
This study looks at the genetic (DNA) features of tumors in children, teens, and young adults with osteosarcoma, Ewing sarcoma, or synovial sarcoma. It may help researchers better understand these cancers by analyzing a fresh tumor sample and a blood sample.
This trial tests a new type of cell therapy called B7-H3 CAR T cells for children and young adults with high-risk osteosarcoma that hasn't spread or worsened after standard chemotherapy. The treatment uses your own immune cells that are modified to attack a protein (B7-H3) found on cancer cells.
This trial studies a combination of two medicines—atezolizumab and cabozantinib—for teenagers and young adults with osteosarcoma that has come back or spread. It aims to slow or shrink the cancer and help control disease that can’t be fully removed with surgery.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
Hear when a new Osteosarcoma in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.